PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
KYMR vs. XBI
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

KYMR vs. XBI

Last updated May 12, 2025

Compare and contrast key facts about Kymera Therapeutics, Inc. (KYMR) and SPDR S&P Biotech ETF (XBI).

XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: KYMR or XBI.

Correlation

The correlation between KYMR and XBI is 1.00, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.

Performance

KYMR vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kymera Therapeutics, Inc. (KYMR) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

KYMR:

142.23%

XBI:

54.04%

Max Drawdown

KYMR:

-14.92%

XBI:

-7.57%

Current Drawdown

KYMR:

-10.45%

XBI:

-7.57%

Returns By Period

KYMR

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

XBI

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Risk-Adjusted Performance

KYMR vs. XBI — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
KYMR
The Risk-Adjusted Performance Rank of KYMR is 3434
Overall Rank
The Sharpe Ratio Rank of KYMR is 3434
Sharpe Ratio Rank
The Sortino Ratio Rank of KYMR is 3535
Sortino Ratio Rank
The Omega Ratio Rank of KYMR is 3535
Omega Ratio Rank
The Calmar Ratio Rank of KYMR is 3333
Calmar Ratio Rank
The Martin Ratio Rank of KYMR is 3131
Martin Ratio Rank
XBI
The Risk-Adjusted Performance Rank of XBI is 55
Overall Rank
The Sharpe Ratio Rank of XBI is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of XBI is 44
Sortino Ratio Rank
The Omega Ratio Rank of XBI is 44
Omega Ratio Rank
The Calmar Ratio Rank of XBI is 77
Calmar Ratio Rank
The Martin Ratio Rank of XBI is 22
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

KYMR vs. XBI - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Kymera Therapeutics, Inc. (KYMR) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

No data
No data
No data
No data
No data

Loading data...

Dividends

KYMR vs. XBI - Dividend Comparison

KYMR has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.18%.

TTM20242023202220212020201920182017201620152014
KYMR
Kymera Therapeutics, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XBI
SPDR S&P Biotech ETF		0.18%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

KYMR vs. XBI - Drawdown Comparison

The maximum KYMR drawdown since its inception was -14.92%, which is greater than XBI's maximum drawdown of -7.57%. Use the drawdown chart below to compare losses from any high point for KYMR and XBI. For additional features, visit the drawdowns tool.

Loading data...

Volatility

KYMR vs. XBI - Volatility Comparison

Loading data...